In a newly released report by MedTech and Pharma Growth Sector (MTPConnect), Australia’s regenerative medicine sector has shown itself to possess all the necessary elements to become a competitive, lucrative and global industry. Extending a bold vision to create a bench to bedside solution, MTPConnect has put forth its plan to deliver global regenerative medicine therapies. This plan dramatically echoes the Centre of Commercialisation for Regenerative Medicine Australia’s (CCRM Australia) own quest to commercialise and translate novel therapies within the sector.
CCRM Australia CEO Silvio Tiziani applauds the report. “This is the first time that a blueprint has been prepared for Australia’s regenerative medicine industry and its one that all the sector can get behind. This very timely publication demonstrates that Australia is well placed to take an active role in this growing segment of the health industry. I congratulate my colleagues on the Ausbiotech Regenerative Medicine Advisory Board for initiating this project.”
CCRM Australia has played an active part in the consultative process leading up to the plan’s publication, having participated in both survey and workshop sessions. With the 6-point plan to move to regenerative medicine therapies from discovery to delivery, CCRM Australia is excited to work with MTPConnect to transform the industry, springboarded by Australia’s previous pioneering success with stem cell transplantation in the 1980’s. For CCRM Australia, this support will come in the form of:
- Enable unique translational platforms that address the key bottlenecks in regenerative medicine commercialisation
- Integrate Australia’s strength in stem cell and biomaterials sciences with dynamic business leadership.
- Engage industry partners, serving as a nexus to link researchers with companies and supporting collaboration
- Internationalise Australian regenerative medicine activities by connecting to leading global RM powerhouses
For Dr Dan Grant, CEO of MTPConnect, there is plenty to be gained, not just for the sector – but for the country. “If we get this right, ongoing success in regenerative medicine could be worth 6$ billion in annual revenue and 6,000 new jobs for Australia by 2035” Dr Grant commented.
With MTPConnect and CCRM Australia working together to provide a stronger future for Australia’s regenerative medicine sector, the future is looking optimistic.
T: +61 421 024 348
T: +61 3 9905 1756
About CCRM Australia
CCRM Australia is an Australian not-for-profit organisation supporting the development of foundational technologies to accelerate the commercialisation of regenerative medicine products and therapies. CCRM Australia’s focus is to bridge the commercialisation gap through a network of scientists, entrepreneurs, academic institutions and industry partners and address bottlenecks in the industry.
About MTPConnect Australia
MTPConnect is a not-for-profit organisation which aims to accelerate the rate of growth of the medical technologies, biotechnologies and pharmaceuticals sector to achieve greater commercialisation and establish Australia as an Asia-Pacific hub for MTP companies. It was formed in November 2015 as part of the Federal Government’s $248 million Industry Growth Centres Initiative.